Investors

Teligent is a specialty generic pharmaceutical company (NASDAQ: TLGT). Our mission is to be a leading player in the specialty generic prescription drug market.

We currently have 30 Abbreviated New Drug Applications (ANDAs) on file at the FDA, representing a total addressable market of approximately $1.9 billion (IMS, October 2017).

We sell a portfolio of prescription topical medicines and a growing number of hospital-based sterile injectable products, including cephalosporins.

As we grow, we will keep our focus on execution, ownership and delivering on what we promise.

Jenniffer Collins
CFO

Recent News

Teligent, Inc. Announces First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%

BUENA, N.J. , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. Announces FDA Approval of Erythromycin Topical Solution USP, 2%

BUENA, N.J. , Nov. 21, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Teligent, Inc. Announces FDA Approval of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%

BUENA, N.J. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic phar...

Learn More

Stock Information

Copyright Nasdaq. Minimum 15 minutes delayed.


Events

Investor Overview